New data from the PACIFIC study presented at EuroPCR (22 May – 25 May, Paris, France) showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease when compared to other commonly used non-invasive cardiac tests. Additionally, data from the SYNTAX III Revolution trial demonstrated the utility of the HeartFlow Analysis –combined with computed tomography (CT) angiogram – in helping clinicians make revascularisation treatment decisions for patients with multivessel disease.
The PACIFIC trial included 208 patients who each underwent a coronary CT angiogram, SPECT, PET and routine three-vessel invasive fractional flow reserve (FFR) measurements. The HeartFlow Analyses were retrospectively obtained from the coronary CT angiogram images. On a per vessel basis, HeartFlow demonstrated significantly greater diagnostic performance (0.94 as measured by area under the receiver operating characteristic curve) compared to coronary CT angiogram (0.83, p<0.001), SPECT (0.70, p<0.001) and PET (0.87, p<0.001). The results of this head-to-head study were presented by Roel Driessen (VU University Medical Center, Amsterdam, The Netherlands).
In the SYNTAX III trial, two heart teams, each comprised of an interventional cardiologist, cardiac surgeon and radiologist, made treatment recommendations based on either data from a coronary CT angiogram plus HeartFlow Analysis or an invasive coronary angiogram. The study, which included more than 200 patients, showed almost perfect agreement in the treatment recommendations of the heart team using coronary CT angiogram plus HeartFlow Analysis and heart team using invasive angiography. SYNTAX III also demonstrated that the HeartFlow Analysis provided supplemental information to a coronary CT angiogram, allowing physicians to understand the functional significance of each lesion, and in some cases, changing the treatment recommendation. The data were presented Patrick W Serruys (National Heart and Lung Institute (NHLI) of Imperial College, London, UK), who is the chairman of the SYNTAX III trial.
Campbell Rogers, chief medical officer, HeartFlow, comments: “The new data presented at EuroPCR show that the HeartFlow Analysis can hold great clinical value in real-world practice for the non-invasive evaluation of coronary artery disease as it provides both anatomic and functional evaluation of coronary lesions. A HeartFlow-guided pathway provides physicians with functional information that was previously only available via invasive measures, and can reduce the need for patients to undergo additional tests. Additionally, by having non-invasive data available to them, physicians can develop a treatment plan ahead of time for a more efficient procedure.”
